Common Contracts
680 similar Underwriting Agreement contracts by Allurion Technologies, Inc., Praxis Precision Medicines, Inc., AC Immune SA, others
7,812,500 Shares Travere Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • November 8th, 2024 • Travere Therapeutics, Inc. • Pharmaceutical preparations • New York
5,500,000 Shares of Common Stock ($0.001 par value per share) KalVista Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • November 4th, 2024 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
ENOVIX CORPORATION 10,416,667 Shares of Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • November 1st, 2024 • Enovix Corp • Miscellaneous electrical machinery, equipment & supplies • New York
Enovix Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 10,416,667 shares of its common stock, par value $0.0001 per share (the “Shares”). The 10,416,667 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,562,500 Shares (the “Option Shares”). The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underwriter, and the term “Underwriters” shall mean eit
BRAZIL POTASH CORP. [●] Common Shares (no par value per share) Underwriting AgreementUnderwriting Agreement • October 23rd, 2024 • Brazil Potash Corp. • Mining & quarrying of nonmetallic minerals (no fuels) • New York
12,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,800,000 Shares of Common Stock TELA Bio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 23rd, 2024 • TELA Bio, Inc. • Surgical & medical instruments & apparatus • New York
Introductory. TELA Bio, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 12,000,000 shares of its common stock, par value $0.001 per share (the “Shares”), and (ii) pre-funded warrants of the Company, in the form attached hereto as Schedule B (the “Pre-Funded Warrants”), to purchase 5,800,000 Shares (the “Warrant Shares”). The 12,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,670,000 Shares as provided in Section 2. The additional 2,670,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” The Offered Shares and the Pre-Funded Warrants are collectively referred to herein as t
23,125,001 Ordinary Shares Pre-Funded Warrants to Purchase 1,875,023 Ordinary Shares Wave Life Sciences Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • September 26th, 2024 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
1,700,000 Shares of Common Stock America’s Car-Mart, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • September 20th, 2024 • Americas Carmart Inc • Retail-auto dealers & gasoline stations • New York
Introductory. America’s Car-Mart, Inc., a Texas corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,700,000 shares of its common stock, par value $0.01 per share (the “Shares”). The 1,700,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 255,000 Shares as provided in Section 2. The additional 255,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters list
12,000,000 Shares Pre-Funded Warrants to Purchase 500,000 Shares of Common Stock scPharmaceuticals Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • August 13th, 2024 • scPharmaceuticals Inc. • Pharmaceutical preparations • New York
● ] Shares Artiva Biotherapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
ALLURION TECHNOLOGIES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 1st, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
1,500,000 Shares Addus HomeCare Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • June 28th, 2024 • Addus HomeCare Corp • Services-home health care services • New York
26,246,720 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 28th, 2024 • Savara Inc • Pharmaceutical preparations • New York
ALLURION TECHNOLOGIES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 26th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
11,250,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,750,000 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2024 • Rezolute, Inc. • Pharmaceutical preparations • New York
Introductory. Rezolute, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 11,250,000 shares of its common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants of the Company (in the form attached hereto as Exhibit C) to purchase 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”). The 11,250,000 shares of Common Stock to be sold by the Company are called the “Firm Shares.” As used herein “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,250,000 shares of Common Stock. The additional 2,250,000 shares of Common Stock to be sold by the Company pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are c
42,744,220 Class A Ordinary Shares ProKidney Corp. UNDERWRITING AGREEMENTUnderwriting Agreement • June 13th, 2024 • Prokidney Corp. • Biological products, (no disgnostic substances) • New York
2,000,000 Shares of Common Stock, par value $0.01, of Dorian LPG Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • June 7th, 2024 • Dorian LPG Ltd. • Deep sea foreign transportation of freight • New York
The undersigned is an owner of shares of common stock, par value $0.01 per share, of the Company (“Shares”) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the “Offering”) for which Jefferies LLC (“Jefferies”) will act as the representative of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the “Underwriting Agreement”) and other underwriting arrangements with the Company with respect to the Offering.
12,743,039 Shares of Common Stock Pre-Funded Warrants to Purchase 7,220,794 Shares of Common Stock Foghorn Therapeutics Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 22nd, 2024 • Foghorn Therapeutics Inc. • Pharmaceutical preparations • New York
Telix Pharmaceuticals Limited [ ● ] American Depositary Shares Representing [ ● ] Ordinary Shares (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • May 17th, 2024 • Telix Pharmaceuticals LTD • Pharmaceutical preparations • New York
The ADSs will be evidenced by American Depositary Receipts (the “ADRs”) to be issued pursuant to a deposit agreement dated as of [ ● ] (the “Deposit Agreement”), among the Company, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and the holders from time to time of the ADRs evidencing the ADSs issued thereunder. The Company shall, following subscription by the Underwriters of the Firm ADSs and, if applicable, the Optional ADSs, deposit, on behalf of the Underwriters, the Shares represented by such ADSs with [ ● ], as custodian (the “Depositary Custodian”) for the Depositary, which shall deliver such ADSs to the Representatives for the account of the several Underwriters for subsequent delivery to the other several Underwriters or the investors, as the case may be.
Silvaco Group, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 30th, 2024 • Silvaco Group, Inc. • Services-prepackaged software • New York
3,318,585 Shares Pre-Funded Warrants to Purchase 221,238 Shares Praxis Precision Medicines, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 29th, 2024 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
4,550,000 Shares of Common Stock RadNet, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 12th, 2024 • RadNet, Inc. • Services-medical laboratories • New York
JEFFERIES LLC RAYMOND JAMES & ASSOCIATES, INC. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022
●] Shares Apogee Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 5th, 2024 • Apogee Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
CELLDEX THERAPEUTICS, INC. 8,520,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • March 1st, 2024 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,520,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 8,520,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,278,000 Shares pursuant to such option collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Leerink Partners LLC and Cowen and Company, LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean Le
23,014,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2024 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
· make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or
17,162,472 Shares of Common Stock Larimar Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2024 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • New York
4,325,000 Shares Corbus Pharmaceuticals Holdings, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 1st, 2024 • Corbus Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Introductory. Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,325,000 shares of its common stock, par value $0.0001 per share (the “Shares”). The 4,325,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 648,750 Shares as provided in Section 2. The additional 648,750 Shares to be sold by the Company are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Securities.”
Alto Neuroscience, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2024 • Alto Neuroscience, Inc. • Pharmaceutical preparations • New York
4,615,384 Shares Tourmaline Bio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 26th, 2024 • Tourmaline Bio, Inc. • Biological products, (no disgnostic substances) • New York
56,700,000 Shares Esperion Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 22nd, 2024 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
Introductory. Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 56,700,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 56,700,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 8,505,000 Shares as provided in Section 2. The additional 8,505,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional under
7,142,858 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 19th, 2024 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • New York
3,168,275 Shares Pre-Funded Warrants to Purchase 1,056,725 Shares Praxis Precision Medicines, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 12th, 2024 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
2 - Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. As used herein, “Applicable Time” is 9:00 p.m. (New York City time) on January 2, 2024. As...Underwriting Agreement • January 4th, 2024 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
3,500,000 Shares Keros Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 4th, 2024 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
14,300,000 Common Shares AC IMMUNE SA UNDERWRITING AGREEMENTUnderwriting Agreement • December 19th, 2023 • AC Immune SA • Pharmaceutical preparations • New York
VERU INC. 45,833,333 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • December 18th, 2023 • Veru Inc. • Pharmaceutical preparations • New York
Veru Inc., a Wisconsin corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 45,833,333 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”). The 45,833,333 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 6,874,999 Shares, which are called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Raymond James & Associates, Inc. (“Raymond James”) and Oppenheimer & Co. Inc. (“Oppenheimer”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as
